is a boutique law firm handling complex and class action litigation, including shareholder derivative litigation, securities class actions, data breach and consumer class actions.

Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs.  Please review any of the case listings  below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company.  Once completed, please return to our office by email to or fax to (405) 239-2112. 

Current Cases

Heartware International, Inc. [NASDAQ: HTWR]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Heartware International, Inc.

Oklahoma City, OK (January 26, 2016) – On January 22, 2016, a securities class action lawsuit was filed in the United States District Court for the Southern District of New York against Heartware International, Inc. (NASDAQ: HTWR). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is June 10, 2014 through January 11, 2016. More specifically, this litigation was filed because on June 20, 2014, the Company assured investors that it had adequately addressed numerous manufacturing and other regulatory failures with its sole manufacturing facility which had been identified by the FDA in a Warning Letter dated June 2, 2014, and that those failures posed no risk to timely MVAD approval. On January 11, 2016, the Company confirmed that nearly half of all patients in the MVAD trial had suffered “serious adverse events” as a result of software issues with MVAD, including significant blood clotting problems. The Company announced that it would indefinitely delay the MVAD trial and that a redesign of MVAD requiring an entirely new MVAD trial may be required. On this news, Heartware shares declined from $40.84 per share to close at $26.50 per share on January 12, 2016.

Plaintiff seeks to recover damages on behalf of all Heartware International, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Tuesday, March 22, 2016 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click here to obtain an investor certification. Once complete, please email this form to, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN: Robin.

Copyright © 2018 Federman & Sherwood. All Rights Reserved.